Published in Am J Transplant on April 22, 2016
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med (2013) 7.98
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res (2004) 7.20
Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. J Hepatol (2014) 3.88
Bicarbonate therapy for prevention of chronic kidney disease progression. Kidney Int (2013) 3.33
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis (2014) 2.80
Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant (2006) 2.53
Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth (2015) 2.34
A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant (2012) 2.24
Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation (2001) 2.13
Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Liver Transpl (2015) 2.01
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl (2007) 1.87
Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med (2009) 1.86
Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant (2011) 1.86
Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant (2008) 1.86
Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant (2008) 1.81
Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant (2005) 1.79
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation (2001) 1.79
Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant (2007) 1.77
Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant (2011) 1.75
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant (2012) 1.55
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J (2007) 1.53
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant (2012) 1.50
OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant (2013) 1.48
Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl (2013) 1.46
Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl (2004) 1.44
Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesth Analg (2004) 1.40
Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc (1988) 1.38
Risk factors of acute renal failure after liver transplantation. Kidney Int (2006) 1.36
Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev (2009) 1.31
Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review. Anesth Analg (2015) 1.27
Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant (2006) 1.25
Protein restriction for diabetic renal disease. Cochrane Database Syst Rev (2007) 1.23
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol (2006) 1.21
Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl (2009) 1.20
Impact of MELD-based allocation on end-stage renal disease after liver transplantation. Am J Transplant (2011) 1.17
Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology (2014) 1.14
De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant (2013) 1.07
Chronic kidney disease after liver transplantation. J Hepatol (2014) 1.06
Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl (2009) 1.06
Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant (2011) 1.05
Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant (2012) 1.04
Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. Transplantation (1990) 1.04
Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol (2013) 1.04
Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction. Am J Transplant (2012) 1.00
Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria. Transpl Int (2013) 0.98
The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant (2014) 0.96
Outcomes and native renal recovery following simultaneous liver-kidney transplantation. Am J Transplant (2012) 0.96
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl (2006) 0.96
Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl (2009) 0.95
N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant (2010) 0.94
Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl (2011) 0.93
Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant (2013) 0.92
Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev (2013) 0.92
Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation (2011) 0.92
Comparison of RIFLE and AKIN criteria in the evaluation of the frequency of acute kidney injury in post-liver transplantation patients. Transplant Proc (2014) 0.90
Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation. BMC Nephrol (2013) 0.90
Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis (1989) 0.90
The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesth Analg (2009) 0.90
Acute kidney injury after liver transplantation: incidence and mortality. Transplant Proc (2014) 0.89
Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl (2006) 0.88
Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation. Am J Transplant (2011) 0.88
Mycophenolate mofetil monotherapy in liver transplantation. Lancet (2001) 0.87
Estimation of glomerular filtration rates after orthotopic liver transplantation: Evaluation of cystatin C-based equations. Liver Transpl (2006) 0.87
Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology (2014) 0.87
Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol (2014) 0.86
Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol (1994) 0.85
The liver neither protects the kidney from rejection nor improves kidney graft survival after combined liver and kidney transplantation from the same donor. Transplantation (1996) 0.85
Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation (2011) 0.83
Chloride-liberal fluids are associated with acute kidney injury after liver transplantation. Crit Care (2014) 0.82
Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl (2009) 0.82
Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant (2014) 0.81
Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans. Transpl Int (2013) 0.81
A new serum cystatin C-based equation for assessing glomerular filtration rate in liver transplantation. Clin Chem Lab Med (2008) 0.80
Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation (2001) 0.80
Alternative definition of acute kidney injury following liver transplantation: based on serum creatinine and cystatin C levels. Transplant Proc (2007) 0.80
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79
Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation (2015) 0.79
The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. J Hepatol (2014) 0.79
Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction. Dig Dis Sci (2010) 0.79
Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant (2015) 0.78
Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation (2010) 0.78
Effect of venovenous bypass on perioperative renal function in liver transplantation: results of a randomized, controlled trial. Hepatology (1996) 0.78
De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev (2014) 0.77
Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int (1993) 0.77
Effects of mycophenolate mofetil introduction in liver transplant patients: results from an observational, non-interventional, multicenter study (LOBSTER). Clin Transplant (2013) 0.77
Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients. Transplantation (2015) 0.77
Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transplant Proc (2009) 0.77
Incidence and impact of rejection following simultaneous liver-kidney transplantation. J Hepatol (2014) 0.76
Management of hypertension in liver transplant patients. Int J Cardiol (2011) 0.76
Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant (2016) 0.75
National Assessment of Early Hospitalization after Liver Transplantation: Risk Factors and Association with Patient Survival. Liver Transpl (2017) 0.75